Pliant Therapeutics, Inc. expected to post a loss of 34 cents a share - Earnings Preview

Pliant Therapeutics

03/08/2026 23:48

Pliant Therapeutics, Inc. PLRX.OQ PLRX.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Pliant Therapeutics, Inc. is for a loss of 34 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Pliant Therapeutics, Inc. is $2.50, about 140.4% above its last closing price of $1.04
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.35
-0.36
-0.32
Beat
10.3
Dec. 31 2026
-0.35
-0.38
-0.38
Met
-0.5
Sep. 30 2025
-0.53
-0.52
-0.43
Beat
17.9​
Jun. 30 2025
-0.70
-0.70
-0.71
Missed
-2.1
​​Mar. 31 2025
-0.71
-0.72
-0.92
Missed
-27
Dec. 31 2024
-0.98
-0.98
-0.82
Beat
16.6​
Sep. 30 2024
-0.96
-0.97
-0.95
Beat
2
Jun. 30 2024
-0.83
-0.85
-0.92
Missed
-8.4
This summary was machine generated August 3 at 22:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)